OncoMatch/Clinical Trials/NCT06477419
A Study of Sacituzumab Govitecan in People With Mesothelioma
Is NCT06477419 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sacituzumab govitecan-hziy for mesothelioma.
Treatment: Sacituzumab govitecan-hziy — Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Mesothelioma
Performance status
ECOG OR KARNOFSKY 0–1
Prior therapy
Must have received: systemic therapy (platinum, pemetrexed, immunotherapy)
Must have received at least one prior systemic therapy (platinum/pemetrexed, immunotherapy or a combination thereof)
Cannot have received: cytotoxic or immunologic systemic therapy
Prior cytotoxic/immunologic systemic therapy within 3 weeks prior to study Day 1 or has not recovered (i.e., CTCAE v5 ≥ Grade 1 at baseline; from clinically significant adverse events due to a previously administered agent (excluding Grade 2 neuropathy)
Cannot have received: investigational agent/device
Currently participating in another study and receiving another study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5K/mcL; Platelet count ≥ 100K/mcL; Hemoglobin > 9g/dL (prior transfusion permitted if not within 7 days of enrollment)
Kidney function
creatinine clearance ≥ 30ml/min (as calculated by Cockcroft-Gault Formula)
Liver function
Total bilirubin ≤1.5 x ULN if no liver metastases or <3 × ULN in the presence of documented Gilbert's Syndrome or liver metastases; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits; AST, ALT ≤ 2.5 x ULN (if liver metastases are present, ≤5 × ULN)
Adequate organ function, defined as: Absolute neutrophil count ≥ 1.5K/mcL; Platelet count ≥ 100K/mcL; Adequate renal function defined as creatinine clearance ≥ 30ml/min (as calculated by Cockcroft-Gault Formula); Hemoglobin > 9g/dL (prior transfusion permitted if not within 7 days of enrollment); Total bilirubin ≤1.5 x upper limit of normal (ULN) if no liver metastases or <3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits; AST, ALT ≤ 2.5 x ULN (if liver metastases are present, ≤5 × ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth · Middletown, New Jersey
- Memorial Sloan Kettering Bergen · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Commack · Commack, New York
- Memorial Sloan Kettering Westchester · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify